About Bioatla (BCAB)
BioAtla, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
- USD3.17
- USD3.28
- USD2.95
- USD4.07
- -16.60%
- --
- 418.29k
- 751.97k
- 156M
- 1.24
- -11.90%
Stock News
yesterday
Reddit CEO talks advertising, says consumers and companies are attracted to the platform
CNBC
yesterday
Cramer explains how to maintain a 'balanced' portfolio as the economy slows
CNBC
yesterday
81% of young people say a 4-day workweek would boost productivity, new CNBC/Generation Lab survey reports
CNBC
yesterday
Montana Technologies Corp. Expands Management Team with Key Appointments
Yahoo
Unlock More Stock Analysis & Reports
Access detailed stock analysis from LSEG including analyst price target estimates.
